首页> 外国专利> METHODS AND PHARMACEUTICAL COMPOSITIONS FOR DIFFERENTIALLY ALTERING GENE EXPRESSION TO PROVIDE NEUROPROTECTION FOR THE ANIMAL CENTRAL NERVOUS SYSTEM AGAINST THE EFFECTS OF ISCHEMIA, NEURODEGENERATION, TRAUMA AND METAL POISONING

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR DIFFERENTIALLY ALTERING GENE EXPRESSION TO PROVIDE NEUROPROTECTION FOR THE ANIMAL CENTRAL NERVOUS SYSTEM AGAINST THE EFFECTS OF ISCHEMIA, NEURODEGENERATION, TRAUMA AND METAL POISONING

机译:对动物中枢神经系统进行神经保护的不同改变基因表达的方法和药物组合物,以对抗缺血,神经生成,创伤和金属中毒

摘要

Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of neurological disorders involving ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and/or stabilizing hypoxia-inducible factor-1a (HIF-1a). HIF-1a is known to provide a neuroprotective benefit under ischemic conditions. In another embodiment, the method is accomplished by differentially reducing, inhibiting or preventing the increased expression of selected genes caused by neurological disorders. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease, Huntington's disease, thalassemia or stroke, or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. Particular examples of such therapeutic agents are the iron chelators deferoxamine (DFO) and deferasirox. Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1a and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia.
机译:用于预处理和/或向动物中枢神经系统提供神经保护以抵抗涉及缺血,创伤,金属中毒和神经变性的神经系统疾病的作用的方法和药物组合物,包括相关的认知,行为和身体损伤。在一个实施方案中,该方法通过刺激和/或稳定低氧诱导因子-1a(HIF-1a)来完成。已知HIF-1a在缺血条件下具有神经保护作用。在另一个实施方案中,通过差异地减少,抑制或预防由神经系统疾病引起的所选基因表达的增加来实现该方法。患有某些与脑缺血风险相关的疾病或病症的风险患者可能会受益,例如,患有阿尔茨海默氏病,帕金森氏病,威尔逊氏病,亨廷顿氏病,地中海贫血或中风的风险患者,或患有头部或脊髓损伤的患者。接受某些可能导致局部缺血的医疗程序的患者也可能会受益。最初,人们认识到缺血或神经变性的可能性。将鼻内治疗剂施用于鼻腔的上部三分之一,以绕过血脑屏障并直接进入中枢神经系统,以避免有害的和潜在的致命副作用。治疗剂包括与铁和/或铜相互作用的那些物质,例如铁螯合剂,铜螯合剂和抗氧化剂。这种治疗剂的具体实例是铁螯合剂去铁胺(DFO)和去铁胺。鼻内施用DFO可以刺激和/或稳定HIF-1a,并提供了一种有效,安全的方法来预处理大脑以预防脑缺血。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号